Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success-Reference-Cited by-同舟云学术

Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success

Published:2017-10-29 Issue:1 Volume:256 Page:83-89
ISSN:0721-832X
Container-title:Graefe's Archive for Clinical and Experimental Ophthalmology
language:en
Short-container-title:Graefes Arch Clin Exp Ophthalmol

Author:

Laiginhas Rita,Silva Marta Inês,Rosas Vitor,Penas Susana,Fernandes Vitor Adriano,Rocha-Sousa Amândio,Carneiro Ângela,Falcão-Reis Fernando,Falcão Manuel Sousa

Publisher

Springer Science and Business Media LLC

Subject

Cellular and Molecular Neuroscience,Sensory Systems,Ophthalmology

Link

http://link.springer.com/article/10.1007/s00417-017-3836-1/fulltext.html

Reference26 articles.

1. Seenu MH (2016) Current approaches to the Management of Diabetic Macular Edema. Am J Manag Care 22:S292–S299

2. Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW (2015) Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 372:1193–1203. https://doi.org/10.1056/NEJMoa1414264

3. Stewart MW (2016) Treatment of diabetic retinopathy: recent advances and unresolved challenges. World J Diabetes 7:333–341. https://doi.org/10.4239/wjd.v7.i16.333

4. Ross EL, Hutton DW, Stein JD, Bressler NM, Jampol LM, Glassman AR (2016) Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for diabetic macular edema treatment: analysis from the diabetic retinopathy clinical research network comparative effectiveness trial. JAMA Ophthalmol 134:888–896. https://doi.org/10.1001/jamaophthalmol.2016.1669

5. Heier JS, Bressler NM, Avery RL, Bakri SJ, Boyer DS, Brown DM, Dugel PU, Freund KB, Glassman AR, Kim JE, Martin DF, Pollack JS, Regillo CD, Rosenfeld PJ, Schachat AP, Wells JA 3rd (2016) Comparison of Aflibercept, Bevacizumab, and Ranibizumab for treatment of diabetic macular edema: extrapolation of data to clinical practice. JAMA Ophthalmol 134:95–99. https://doi.org/10.1001/jamaophthalmol.2015.4110

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Brolucizumab versus aflibercept for recalcitrant diabetic macular edema in Indian real-world scenario – The BRADIR study;American Journal of Ophthalmology Case Reports;2024-12

2. Anti-Vascular Endothelial Growth Factor Treatment in Diabetic Macular Edema-Results from a Large Single Center Cohort with Bevacizumab As First-Line Therapy;Retina;2024-03-12

3. Safety and Efficacy of Brolucizumab in the Treatment of Diabetic Macular Edema and Diabetic Retinopathy: A Systematic Review and Meta-Analysis;Seminars in Ophthalmology;2023-10-18

4. One Year Results of Faricimab for Aflibercept-Resistant Diabetic Macular Edema;Clinical Ophthalmology;2023-08

5. Persistent diabetic macular edema: Definition, incidence, biomarkers, and treatment methods;Survey of Ophthalmology;2023-03